{"id":"W4403202763","doi":"10.1016/s2666-5247(24)00163-0","title":"Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Microbe","topic":"Viral Infections and Outbreaks Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nova Scotia Health Authority; Izaak Walton Killam Health Centre; Dalhousie University; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Defense Threat Reduction Agency; Battelle; Canadian Immunization Research Network; Leidos; Frederick National Laboratory for Cancer Research; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; NHLBI Division of Intramural Research; Public Health Agency of Canada; Public Health Agency","keywords":"Medicine; Ebola virus; Booster dose; Vaccination; Ebola vaccine; Immunogenicity; Clinical trial; Booster (rocketry); Internal medicine; Randomized controlled trial; Antibody; Pediatrics; Immunization; Disease; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001161841,0.0001363946,0.0008487965,0.00006125384,0.00009271528,0.00002736462,0.0002224853,0.00005600744,0.00009636974],"category_scores_gemma":[0.0003334603,0.00006842846,0.0002623186,0.0001995837,0.0001023826,0.00007132528,0.0002019054,0.000164985,0.000001265223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003197614,"about_ca_system_score_gemma":0.0001563558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001725826,"about_ca_topic_score_gemma":0.00006004492,"domain_scores_codex":[0.9985741,0.0002420948,0.0006359658,0.0001853745,0.0001578791,0.0002045445],"domain_scores_gemma":[0.9986495,0.0004872487,0.00022214,0.0004085815,0.0001771978,0.00005536541],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5560999,0.0006959992,0.00001006826,0.0002476488,0.0005254297,0.000001140245,0.0001448497,0.000002088885,0.4380502,0.00006532168,0.0004963847,0.003660995],"study_design_scores_gemma":[0.9023017,0.001252824,0.0002427564,0.000407185,0.001126369,0.000008338141,0.00002988986,0.003531692,0.08837924,0.000153368,0.00249233,0.00007435336],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820599,0.004781305,0.0007830819,0.001058028,0.0001872247,0.01049725,0.0004578283,0.0000142558,0.0001611202],"genre_scores_gemma":[0.9971611,0.0008202454,0.0001233856,0.000101617,0.0001526688,0.0002330568,0.00003245861,0.00001920796,0.00135626],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3496709,"threshold_uncertainty_score":0.2790432,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04765059518969653,"score_gpt":0.3885643690924924,"score_spread":0.3409137739027959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}